Valneva IPO Presentation Deck

Phase 2 Month 0-2-6 Schedule Showed High Immunogenicity V SCRS (Seroconversion Rates) after Completion of Primary Vaccination Series Ranged From 93.8% to 98.8% in Highest Dose Seroconversion Rate (%) with 95% Confidence Intervals Seroconversion Rates for OspA-specific IgG by ELISA, per Serotype, D208, PP Population 100 80 60 40 20 0 LLLLLL ST1 I ST2 Treatment Group = 135 µg ST3 Valneva - Roadshow Presentation ST4 ST5 ☐ 180 µg No statistically significant differences observed between 135µg and 180µg treatment groups ■ Placebo ST6 April 2021 13

View entire presentation